{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:41:27Z","timestamp":1792244487590,"version":"4.4.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jfma.2026.10.016","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:19:33Z","timestamp":1792235973000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expanding antiviral therapy in chronic hepatitis B: Evidence, uncertainties, and clinical considerations"],"prefix":"10.1016","author":[{"given":"Yingying","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2026.10.016_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfma.2026.09.015","article-title":"Expanding treatment guidelines for chronic hepatitis B: a narrative review","author":"Lin","year":"2026","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"10.1016\/j.jfma.2026.10.016_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jfma.2026.10.016_bib3","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2024.11.018","article-title":"Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis","volume":"82","author":"Lai","year":"2025","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jfma.2026.10.016_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1473-3099(20)30692-7","article-title":"Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial","volume":"21","author":"Hsu","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jfma.2026.10.016_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2468-1253(24)00431-X","article-title":"Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial","volume":"10","author":"Lim","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626009526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626009526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:52:11Z","timestamp":1792241531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664626009526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":5,"alternative-id":["S0929664626009526"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.10.016","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding antiviral therapy in chronic hepatitis B: Evidence, uncertainties, and clinical considerations","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}